Skip to main content

Human CD28 Alexa Fluor™ Plus 488-conjugated Antibody

R&D Systems, part of Bio-Techne | Catalog # AF-342-PBAFP488

Catalog #
Availability
Size / Price
Qty
Loading...
AF-342-PBAFP488

Key Product Details

Species Reactivity

Human

Applications

Immunohistochemistry, Flow Cytometry, Immunocytochemistry, Agonist Activity, CyTOF-ready

Label

Alexa Fluor Plus 488 (Excitation = 493 nm, Emission = 518 nm)

Antibody Source

Polyclonal Goat IgG

Product Specifications

Specificity

Detects human CD28 in direct ELISAs and Western blots.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Applications for Human CD28 Alexa Fluor™ Plus 488-conjugated Antibody

Application
Recommended Usage

Agonist Activity

Optimal dilution of this antibody should be experimentally determined.

CyTOF-ready

Optimal dilution of this antibody should be experimentally determined.

Flow Cytometry

Optimal dilution of this antibody should be experimentally determined.

Immunocytochemistry

Optimal dilution of this antibody should be experimentally determined.

Immunohistochemistry

Optimal dilution of this antibody should be experimentally determined.

Background: CD28

CD28 and CTLA-4, together with their ligands, B7-1 and B7-2, constitute one of the dominant costimulatory pathways that regulate T and B cell responses. CD28 and CTLA-4 are structurally homologous molecules that are members of the immunoglobulin (Ig) gene superfamily. Both CD28 and CTLA-4 are composed of a single Ig V‑like extracellular domain, a transmembrane domain and an intracellular domain. CD28 and CTLA-4 are both expressed on the cell surface as disulfide-linked homodimers or as monomers. The genes encoding these two molecules are closely linked on human chromosome 2 and mouse chromosome 1. Mouse CD28 is expressed constitutively on virtually 100% of mouse T cells and on developing thymocytes. Cell surface expression of mouse CD28 is down-regulated upon ligation of CD28 in the presence of PMA or PHA. In contrast, CTLA-4 is not expressed constitutively but is up-regulated rapidly following T cell activation and CD28 ligation. Cell surface expression of mouse CTLA-4 peaks approximately 48 hours after activation. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20-100 fold higher affinity than CD28. CD28/B7 interaction has been shown to prevent apoptosis of activated T cells via the upregulation of Bcl-xL. CD28 ligation has also been shown to regulate Th1/Th2 differentiation.

References

  1. Lenschow, D.J. et al. (1996) Annu. Rev. Immunol. 14:233.
  2. Hathcock, K.S. and R.J. Hodes (1996) Advances in Immunol. 62:131.
  3. Ward, S.G. (1996) Biochem. J. 318:361.

Alternate Names

CD28

Entrez Gene IDs

940 (Human); 12487 (Mouse); 102146670 (Cynomolgus Monkey)

Gene Symbol

CD28

UniProt

Additional CD28 Products

Product Documents

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human CD28 Alexa Fluor™ Plus 488-conjugated Antibody


This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.

For research use only

Loading...
Loading...
Loading...
Loading...
Loading...
Loading...